Peptide Discovery

AI-Driven Peptide Discovery & Synthesis

From Protein Surface Dynamics
to Rational Peptide Therapeutics.

Structure-first generation of linear and macrocyclic peptides—integrating dynamic hotspot discovery, de novo backbone and sequence design, cyclization-aware chemistry, custom peptide synthesis, and experimental validation.

Target-informed designNoncanonical amino acidsDesign–Make–Test–LearnCustom peptide synthesis
Illustrative molecular schematicStructure-led peptide design
Schematic illustrates scaffold geometry—not a predicted or experimentally determined binding pose.
Hotspot → BackboneDynamic binding-site intelligence
Backbone → SequenceStructure-conditioned generation
Sequence → ChemistryCyclization and ncAA design
Prediction → ValidationSynthesis, biophysics and biology
Two complementary molecular formats

Sequence flexibility or conformational control.
Designed for the target.

A peptide’s therapeutic potential depends on the shape it adopts, the interactions it makes, and how it behaves in a biological system. PozeSCAF designs across both linear and macrocyclic architectures rather than treating cyclization as an afterthought.

Linear peptides

Sequence-driven molecular recognition

Generate linear peptide binders for accessible and shallow protein surfaces, protein–protein interaction sites and conjugation applications. Optimize sequence-level contacts, selectivity and biochemical stability.

Design priorities: hotspot anchors, secondary structure, solubility, protease stability, affinity maturation and conjugation vectors.

Macrocyclic peptides

Conformation-guided precision

Explore cyclized peptide scaffolds to constrain binding geometry and modulate stability and exposure. Ring size, closure chemistry and backbone stereochemistry are designed around the target interaction—not selected by a generic rule.

Design priorities: head-to-tail or side-chain closure, disulfide strategies, ring strain, noncanonical residues, permeability and proteolytic stability.

PozeSCAF peptide design intelligence

Discover the binding hotspot before designing the sequence.

Our workflow begins with target conformation and solvent behavior. Molecular dynamics and mixed-solvent sampling expose transient binding features, distinguish useful anchoring chemistries, and translate surface interactions into designable peptide constraints.

  • Dynamic hotspot mapping: identify shallow, flexible and cryptic recognition sites across target ensembles.
  • Hotspot-conditioned scaffold generation: generate peptide geometry around productive anchor residues rather than relying only on sequence enumeration.
  • Structure-aware sequence generation: match amino acid chemistry and stereochemistry to the selected 3D scaffold and target environment.
Scientific design principle · original schematic. Illustrative mechanism—not a molecular simulation output.
Integrated discovery engine

One connected workflow.
From molecular hypothesis to validated lead.

A structure-led discovery process combining AI generation, physics-informed ranking, early developability filtering, and experimental feedback.

01 / MAP

Map dynamic hotspots

MD, solvent probes, cryptic pockets and peptide pharmacophore constraints.

02 / GENERATE

Generate backbones

GenSCAF produces target-conditioned 3D linear and cyclic scaffolds.

03 / DESIGN

Design sequences

DesignSCAF selects amino acids compatible with scaffold and binding environment.

04 / FILTER

Filter & cyclize

Geometry-aware closure selection and sequence, synthesis and immune-risk screens.

05 / MODEL

Model & optimize

Complex prediction, relaxation, interface scoring, MD and ncAA design.

06 / TEST

Synthesize & test

Peptide synthesis, SPR or relevant assays, SAR and iterative refinement.

Design → Sequence → Validate → Predict → Refine → Profile → Optimize. Biological results feed the next design cycle.

Discuss Your Target →

Mechanism-guided selectivity & developability

Optimize the full peptide—not binding alone.

Strong target affinity is only the beginning. Peptide leads must also meet stability, safety, route-of-administration and manufacturing constraints.

Rational cyclization

Evaluate head-to-tail, head-to-side-chain, tail-to-side-chain, disulfide and side-chain-to-side-chain options for geometric compatibility and synthetic feasibility.

CONFORMATIONAL DESIGN

Noncanonical residues

Explore D/L substitutions, backbone and side-chain modifications, and residue-level mutation while protecting essential hotspot interactions.

CHEMICAL EXPLORATION

Immunogenicity & liabilities

Assess potential MHC binding, epitope risk, oxidation, deamidation, cleavage, aggregation and other sequence-level liabilities.

RISK-INFORMED RANKING

Structure & interface quality

Use peptide–target complex predictions, structural confidence, Rosetta refinement, interface energetics and molecular dynamics as complementary evidence.

PHYSICS VALIDATION

ADMET & exposure

Prioritize solubility, permeability, half-life, hemolysis risk, nonspecific binding and route-specific exposure requirements.

THERAPEUTIC PROPERTIES

Synthesis-ready leads

Close the loop through peptide synthesis, biophysical binding measurements, biological testing, residue scans and affinity maturation.

BENCH TRANSLATION
Evidence-led design: Predicted structural confidence, interface scores, immunogenicity and ADMET estimates are prioritization tools—not substitutes for experimental pharmacology or safety data.
Research applications

Designed for challenging protein surfaces.

The illustrations below are original schematics of peptide–target design across different therapeutic contexts. They do not depict disclosed target identities or experimentally determined structures.

Linear peptides & conjugates

Target dynamic shallow pockets, mature high-affinity binders and explore peptide-drug conjugate architectures.

ONCOLOGY

Linear-to-cyclic refinement

Explore conversion of a linear binder into a conformationally constrained cyclic scaffold to improve its property profile.

METABOLIC BIOLOGY

Macrocyclic shape optimization

Adjust cyclic peptide geometry and side-chain presentation to improve modeled protein–protein contacts.

IMMUNOLOGY
Discovery experience: Illustrative internal research programs span peptide hit identification, affinity maturation, linear-to-cyclic optimization and peptide–drug conjugate design. Target identities, quantitative results and client-specific information are deliberately omitted from this public-facing page.
SynthesisWhat we synthesize

One peptide chemistry partner.
Multiple molecular architectures.

Designs do not stop on screen. PozeSCAF’s peptide chemistry team translates designs into purified, characterized research molecules, so each analogue can go straight into the next binding or biology experiment. Select the sequence, conformational constraint, and functional modification your experiment requires; chemistry and analytical specifications are defined for each project.

01 / SEQUENCE CHEMISTRY

Linear Peptides

Custom research sequences for binding studies, enzyme assays, target validation and peptide therapeutic programs.

3–60 residuesCustom sequences
02 / CONFORMATIONAL CONTROL

Cyclic & Macrocyclic Peptides

Constrained architectures, including ring-closed peptides and custom macrocycles, designed for project-specific structural requirements.

CyclizationMacrocycles
03 / STRUCTURAL CONSTRAINTS

Disulfide & Stapled Peptides

Cysteine-rich, disulfide-bridged and staple-constrained peptide formats for investigating conformational stabilization.

Disulfide bondsStapling
04 / FUNCTIONAL MODIFICATION

Phosphorylated Peptides

Site-specific phosphopeptides to support phosphorylation-dependent recognition and signaling research.

Phosphoester chemistrySignaling assays
05 / CONJUGATION CHEMISTRY

Biotinylated & PEGylated Peptides

Terminal or side-chain biotin attachment and PEG-spacer strategies for assay formats and specialized molecular constructs.

BiotinPEG₂–PEG₂₀
06 / ASSAY-READY CONSTRUCTS

Fluorescent Peptides & Libraries

Fluorescently tagged sequences and focused peptide libraries for imaging, binding studies and systematic SAR exploration.

Fluorescent labelsPeptide libraries
About the illustrations: Illustrations are explanatory molecular schematics, not atomically resolved structures. Exact modifications, scales and analytical methods are agreed during project scoping.
Each stage answers one question; experimental results close the loop.
A unified design–make–test platform

AI and physics connected to experimental biology.

PozeSCAF combines peptide design engines with molecular simulations, medicinal chemistry, custom peptide synthesis and biological assays so each stage answers a specific drug-discovery question.

  • GenSCAF: target-constrained 3D peptide backbone generation.
  • DesignSCAF: backbone-aware amino acid sequence generation.
  • AxDrug™: integrated modeling, property prediction and multiparameter optimization.
  • Peptide synthesis: purified, characterized peptides made for each design round, from linear sequences to macrocycles and specialty modifications.
  • Experiment: binding assays, biology and closed-loop design refinement.

Platform capabilities are described based on the supplied PozeSCAF presentation; suitability and performance depend on the target and project scope.

Scientific FAQs

Questions peptide discovery teams ask.

What is the difference between a linear and a macrocyclic peptide, and when is each preferable?

A linear peptide is a chain of amino acids with free ends, so it can take many shapes. In a macrocyclic peptide the ends, or selected side chains, are joined into a ring, which limits the shapes it can adopt. Macrocyclization can restrict conformations, potentially helping potency, selectivity or proteolytic stability, but it does not automatically improve permeability or oral exposure. The better choice depends on the binding surface, ring geometry, chemistry and measured properties.

Which ways of closing a ring are considered?

Head-to-tail, head-to-side-chain, tail-to-side-chain, disulfide and side-chain-to-side-chain options can be evaluated for geometric compatibility and synthetic feasibility. Ring size, closure chemistry and backbone stereochemistry are designed around the target interaction rather than chosen by a generic rule.

Can your workflow design peptides for shallow or cryptic binding sites?

Yes, the workflow is designed to use dynamic protein ensembles, mixed-solvent sampling and hotspot-conditioned scaffold generation to investigate challenging target surfaces. Prospective binding and functional validation are still required.

Why start from protein dynamics instead of a single structure?

Binding features can open, close or shift as a protein moves, and some appear only transiently. Molecular dynamics and mixed-solvent sampling across target ensembles can expose these features, so peptide constraints are not based on a single static snapshot.

What do GenSCAF and DesignSCAF do?

GenSCAF produces target-conditioned 3D linear and cyclic peptide backbones around the hotspots. DesignSCAF then selects amino acids that suit the backbone and the binding environment. Together they move from geometry to sequence.

How are peptides prioritized before synthesis?

Candidate ranking considers target contacts, structural confidence, cyclization feasibility, energetic and interface evidence, immunogenicity risk, solubility, permeability, stability and synthesis-related constraints.

Which properties are weighed besides binding?

Solubility, permeability, half-life, hemolysis risk, nonspecific binding and route-specific exposure requirements are considered alongside affinity. Stability, safety, route of administration and manufacturing constraints can each decide whether a binder becomes a lead.

What peptide formats and modifications can PozeSCAF synthesize?

The service covers linear peptides (3–60 amino acids), cyclic and macrocyclic peptides, disulfide-containing peptides and stapled peptides, including cysteine-stapled formats. Listed modifications include phosphorylation, biotinylation, PEGylation (PEG₂–PEG₂₀) and fluorescent labeling, and custom peptide libraries for screening and structure–activity studies are also offered. Feasibility depends on sequence and chemistry and is confirmed when the project is scoped.

Can I include nonstandard residues or specific stereochemistry?

Yes, you can state stereochemistry or nonstandard residues in your quote request. Whether a particular residue or arrangement can be made is confirmed when the project is scoped.

How are synthesized peptides purified and characterized?

Purification is supported with HPLC, which separates the target peptide from related by-products so the main peak can be collected. Identity and quality are then evaluated using methods agreed for the project, and the agreed analytical documentation is supplied with the material. Purity and amount should be specified with the project brief; achievable specifications depend on the sequence, modifications and scope.

What should a synthesis request include, and how long will it take?

Provide the sequence(s), terminal groups, stereochemistry or nonstandard residues, cyclization type, modifications, required quantity and purity, analytical expectations, intended assay and delivery constraints. Timing depends on sequence length and difficulty, any cyclization or modification, the purification needed and the quantity requested; a timeline is agreed as part of the scoped quote.

Can I order a peptide without a full discovery program?

Yes. You can commission a single research peptide, a focused library or an iterative discovery program, and you do not need a finished design to start. If you are still deciding between formats, describe the biological question and the team can discuss linear and constrained options with you.

How does synthesis fit into the discovery loop?

Synthesis is the Make step of a loop of design, make, test and learn. Each purified, characterized analogue returns binding or biological results that inform the next design, so every analogue can answer a question.

Do computational predictions replace experiments?

No. Predicted structural confidence, interface scores, immunogenicity and ADMET estimates are prioritization tools. Binding, function and safety are established through synthesis, biophysical measurements, biological testing and appropriate pharmacology.

How does a project start?

With a target and a biological question. The discovery team can assess the target, identify hotspots, and scope linear or macrocyclic peptide design, synthesis and biological validation for the program.